Reports from the 2017 PDA/FDA Joint Regulatory Conference
CBER Director Peter W. Marks discusses his perspective on innovation
Quality is essential no matter how revolutionary the drug product. That concept permeated the 2017 PDA/FDA Joint Regulatory Conference: “Ensuring Product Quality in an Era of Innovative Therapies,” Sept. 11–13, in Washington, D.C.
Three sessions in particular emphasized the spirit behind the theme of the meeting.